{"entity":{"id":"nct06730347","kind":"trial","name":"A Study of Lorigerlimab in Participants With Advanced Solid Tumors","aka":[],"tldr":"A phase 2 trial of Lorigerlimab in ovarian cancer and endometrial cancer, run by MacroGenics, now recruiting.","summary":"A Study of Lorigerlimab in Participants With Advanced Solid Tumors is a phase 2 interventional study registered as NCT06730347 by MacroGenics, with 80 participants planned, started 2025-05-01 and due to reach its primary completion in 2027-07. Interventions recorded: Lorigerlimab. Conditions listed: Platinum-resistant Ovarian Cancer, Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma, Clear Cell Adenocarcinoma of Ovary. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06730347","url":"https://clinicaltrials.gov/study/NCT06730347"}],"tags":["ctgov-ingest"],"related":[],"cancers":["ovarian","endometrial"],"sections":[],"technologies":[],"targets":[],"drugs":["lorigerlimab"],"companies":["macrogenics"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06730347","phase":"2","setting":"A Phase 2 Multicohort Study to Evaluate Lorigerlimab in Participants With Advanced Solid Tumors","sponsor":"MacroGenics","enrolled":80,"outcomes":[]},"route":"/trials/nct06730347/","neighbours":{"cancer":[{"id":"endometrial","kind":"cancer","name":"Endometrial cancer","route":"/cancers/endometrial/"},{"id":"ovarian","kind":"cancer","name":"Ovarian cancer","route":"/cancers/ovarian/"}],"drug":[{"id":"lorigerlimab","kind":"drug","name":"Lorigerlimab","route":"/drugs/lorigerlimab/"}],"company":[{"id":"macrogenics","kind":"company","name":"MacroGenics","route":"/companies/macrogenics/"}]}}